(#ASX: $AEB) #AlgaeTec to Exclusively License Pharmaceutical Delivery Platform— Algae.Tec (@AlgaeTec_) February 11, 2018
Read more: https://t.co/0OJlEw0Xr2#medicinal #pharmaceutical #algae #plantbased #Ausbiz #investing #news pic.twitter.com/UvVpcteIIv
The company has signed an agreement with a private Australian-based pharmaceutical delivery company, NS Technologies (NST) for the delivery platform technology.
Lower dosage with an effective outcome
The technology is one where a ‘mini-emulsion’ was developed to allow complex molecules to penetrate the epidermis skin layer, and enter the subdermal layer of the human body.
The mini-emulsion droplets filter through the epidermal layer, in an effective, “slow release” manner, allowing lower dosages, with an effective outcome.
This mini-emulsion base component requires a selected vegetable oil, which is ideally suited to specific algal oils.
Algae.Tec’s algal oils could be the base component
Under the agreement, Algae.Tec will acquire 19.9% of NST and exclusively license NST’s delivery platform technology for use across any medical application developed by Algae.Tec.
NST has also agreed to use AEB’s algae oil as the base component of its emulsion delivery platform.
The companies are aiming to develop a range of mini-emulsion pharmaceutical products for both human and veterinary purposes using selected algal oils.